Golden State Equity Partners’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-69,810
Closed -$1.96M 1330
2026
Q1
$1.96M Buy
69,810
+35,963
+106% +$957K 0.15% 161
2025
Q4
$843K Buy
33,847
+4,942
+17% +$125K 0.14% 171
2025
Q3
$737K Buy
28,905
+108
+0.4% +$2.67K 0.12% 194
2025
Q2
$698K Buy
28,797
+10,348
+56% +$241K 0.13% 193
2025
Q1
$468K Buy
18,449
+261
+1% +$6.83K 0.09% 257
2024
Q4
$483K Buy
18,188
+16,410
+923% +$445K 0.09% 241
2024
Q3
$51.5K Buy
+1,778
New +$51.9K 0.03% 373
2023
Q4
$734K Buy
25,493
+14,607
+134% +$442K 0.18% 129
2023
Q3
$361K Buy
10,886
+176
+2% +$6.22K 0.1% 214
2023
Q2
$393K Sell
10,710
-4,857
-31% -$189K 0.11% 216
2023
Q1
$635K Buy
+15,567
New +$672K 0.34% 79
2022
Q1
$265K Sell
5,128
-14,312
-74% -$743K 0.13% 157
2021
Q4
$1.15M Buy
19,440
+456
+2% +$22.6K 0.58% 44
2021
Q3
$817K Buy
18,984
+9,870
+108% +$437K 0.33% 71
2021
Q2
$357K Buy
9,114
+3,040
+50% +$118K 0.14% 156
2021
Q1
$220K Sell
6,074
-468
-7% -$16.6K 0.13% 154
2020
Q4
$240K Buy
+6,542
New +$240K 0.17% 142

Other funds holding PFE

Golden State Equity Partners's PFE Position: Q2 2026 in Review

Golden State Equity Partners sold out of Pfizer (PFE) in Q2 2026, closing a stake of 69,810 shares — an estimated $1.96M sold.

Golden State Equity Partners first reported a position in PFE in Q4 2020 and held it in 17 quarters. The position peaked at $1.96M in Q1 2026. 1,393 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Golden State Equity Partners reported no remaining Pfizer position as of Q2 2026 after selling out during the quarter.
  • Golden State Equity Partners sold 69,810 Pfizer shares in Q2 2026, an estimated $1.96M.
  • Golden State Equity Partners first reported a position in Pfizer in Q4 2020 and held it in 17 quarters.
  • Golden State Equity Partners's Pfizer position peaked at $1.96M in Q1 2026.
  • 1,393 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Golden State Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.